Study shows promise of precision medicine for most common type of lymphoma
A recent study shows that patients with a specific molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to ibrutinib (Imbruvica) than patients with another molecular subtype of the disease.
Diffuse large B-cell lymphoma (DLBCL) - an aggressive (fast-growing) lymphoma - is the most common type of non-Hodgkin’s lymphoma (NHL).
The phase II trial, conducted by the National Cancer Institute (NCI) and Pharmacyclics, showed that patients with the activated B-cell-like (ABC) subtype of DLBCL were more likely to respond to ibrutinib than patients with the germinal center B-cell-like (GCB) subtype of DLBCL.
